In the 2020 ER and PR guidelines from the American Society of Clinical Oncology and the College of American Pathologists (ASCO-CAP), the cut-off that indicates patients who will benefit from endocrine therapy remains at 1% of cancer nuclei stained for ER, irrespective of staining intensity. This evidence concerns the gene ESR1 and cancer.